



한국판 CERAD 평가집 (CERAD-K)의 개발과정 및 의의

2009. 11. 28.

Jung Hie Lee, M.D., Ph.D.

Department of Psychiatry

Kangwon National University School of Medicine



Increased Life Expectancy

- A new epidemic of age-related disorders, particularly dementia, have been unmasked.
- As our life expectancy increases and the aging population constitutes larger proportion, the question is:
- *What merit is there in lengthening life if quality is not preserved?*

Dementia

- *Definition* : An acquired and sustained deterioration of memory and other intellectual functions in an alert patient
 - : Conducts everyday activities less well, relative to past performance
- Result from brain dysfunction and is a Sx of many disease

*** 2 Basic Questions in the evaluation of suspected dementia pt.**

- (1) Is the patient truly demented?**
- (2) If so, what is the cause?**

Cause of Dementia

I. Cerebral neurodegenerative disorders

Alzheimer's disease (~50%)

Pick's disease (FTD)

Parkinson's disease / Diffuse Lewy Body
dementia

Huntington's disease -----

II. Other disorders causing cerebral dysfunction (some potentially are reversible)

Vascular dementia (20~30%)

Intracranial neoplasm

Trauma

NPH

Hypothyroidism


Vit B12/ folate deficiency

AIDS -----

Dr. Alois Alzheimer




Auguste D








Neurofibrillary tangles
from Auguste D, drawn by
Alzheimer

Senile plaque







Normal



Alzheimer's



Crump Institute for Biological Imaging



Problems in Dementia Research

A broad variety of

1. Diagnostic criteria
2. Testing methods
3. Classifications of
disease severity




Diagnostic criteria for AD

- DSM-III-R
- DSM-IV
- ICD-10
- NINCDS-ADRDA

(National Institute of Neurological and
Communicative Disorders and Stroke – Alzheimer's
Disease and Related Disorders Association)

Diagnostic Criteria for VD

- DSM-III-R
- DSM-IV
- ICD-10
- Hachinski ischemic score
- ADDTC
(California AD Diagnostic and Treatment Center)
- NINDS-AIREN
(National Institute of Neurological Disorders and Stroke – Association Internationale pour la Recherche et l'Enseignement en Neurosciences)



Many investigators believed that lack of consistency had created confusion, which affected clinical, neuropathological, and epidemiological research

Comparison of research findings from individual research centers was not possible because of the variety of approaches to testing

**Requirement of Standardized
diagnostic & evaluation instrument**



CERAD

**Consortium to Establish a Registry for
Alzheimer's Disease**

CERAD – Background

- Health Research Extension Act (1985, US Congress)
National Institute on Aging (NIA) as authorized organization
- CERAD was funded by NIA in 1986 to develop a battery of standardized instruments with AD.

- 1. Create uniformity in enrollment criteria**
- 2. Permitting the pooling of information across sites**
- 3. Making comparison of research findings possible**



CERAD – Sites & translations

- **16 university medical centers throughout the US joined to form CERAD (initially)**
- Translation languages (12 languages)
 - Bulgarian, Czech, French, Spanish, Italian, German, Portuguese, Dutch
 - Korean, Japanese, Chinese, Hebrew
- Have promoted to form an international network of investigators

CERAD – Components


- Three major components of CERAD battery
 - **Clinical assessment**
 - **Neuropsychological assessment**
 - Neuropathological assessment

- Several other Assessments in CERAD
 - Neuroimaging
 - **Behavioral Rating Scale for Dementia (BRSD)**
 - Extrapyrarnidal dysfunction in AD (EPDAD)
 - Family history of AD
 - the use of community services in the care of patients with AD

CERAD neuropsychological assessment battery

Very popular in many clinical and research settings because of its brevity, portability, and usefulness in evaluating elderly patients with dementia, including those with very mild cognitive symptoms

- J1. Verbal Fluency
- J2. Boston Naming Test
- J3. Mini-Mental State Exam
- J4. Word List Memory
- J5. Constructional Praxis
- J6. Word List Recall
- J7. Word List Recognition
- J8. Constructional Recall
- J9. Trail Making A & B



Korean version of CERAD assessment packet (CERAD-K): Clinical & neuropsychological batteries

1. Translation
2. Reliability & Validity of Cognitive tests

Key issue in development of CERAD-K

- Tried to ensure the equivalence to the original CERAD batteries for comparability in the international study

1. Semantic equivalence

2. Technical equivalence

3. Construct equivalence



Translation of CERAD packet into Korean

1. Basic translation Process

- 1) Translated into Korean by a psychiatrist
- 2) Psychiatrists and neurologists reviewed the translated material
- 3) preliminarily applied to normal controls (N=43), and dementia patients (N=55)
- 4) several items were modified to improve comprehensibility and applicability.

Translation of CERAD packet into Korean

2. Specific considerations for each NP test

1) 15-item Boston Naming Test

- Chose 15 items from K-BNT
- Considering the word frequency
⇒ high, medium and low frequency groups

2) Word List Memory / Recall / Recognition

- Considering the word frequency, mental imagery, primarily
- Considering semantic category, number of syllables, secondarily



Translation of CERAD into Korean

3) MMSE

- adapt some items of MMSE-K (MMSE-KC)

4) Verbal Fluency, Constructional Praxis & Recall

- keep the test format of the original version

3. Back Translation

Discussed with the CERAD headquarter in Duke University
(Dr. Heyman and Dr. Fillenbaum)

Reliability of CERAD-K

- Standardization of administration
 - Instruction manual
 - Training with video-taped material
 - Consensus diagnostic conference (every week)
- Inter-rater reliability
 - Simultaneous rating by tester and scorer
 - 21 subject (14 dementia / 7 control)
- Test-retest reliability : 1 month interval
 - 20 subject (10 dementia / 10 control)

Inter-rater reliability

Test Items	Pearson's correlation coefficient	p-value
Blessed Dementia Rating Scale	0.970	< 0.001
Short Blessed Test	0.998	< 0.001
Verbal Fluency	0.999	<0.001
Boston Naming Test (K)	0.991	< 0.001
MMSE	0.999	< 0.001
Word list Memory	0.999	< 0.001
Construction Praxis	0.969	< 0.001
Word List Recall	0.999	< 0.001
Word List Recognition	0.999	< 0.001
Constructional Recall	0.994	< 0.001

Test-retest reliability

Test Items	Pearson's correlation coeffecient	p-value
Verbal Fluency	0.704	< 0.01
Boston Naming Test (K)	0.879	< 0.01
MMSE	0.578	< 0.05
Word list Memory	0.652	< 0.01
Construction Praxis	0.544	< 0.05
Word List Recall	0.653	< 0.01
Word List Recognition	0.741	< 0.01
Constructional Recall	0.612	< 0.01

Validity of cognitive tests in CERAD-K

- Subjects

- 106 patients with clinically diagnosed dementia
 - Alzheimer's disease : 78 cases
 - Non Alzheimer's disease : 46 cases
- 186 non-demented elderly subjects

- Discriminant validity

- Construct validity

Table 3. Comparisons of the Scores on the CERAD-K Cognitive Tests in the Control Group With Those of the Dementia and Alzheimer's Disease (AD) Groups

Test	Control (<i>n</i> = 186)	Dementia (<i>n</i> = 106)	AD (<i>n</i> = 78)
Blessed Dementia Scale ^a			
<i>M</i> (<i>SD</i>)	0.0 (0.0)	5.5 (3.5)*	5.2 (3.4)*
Range	0.0–0.5	0.5–17.0	0.5–17.0
Short Blessed Test ^a			
<i>M</i> (<i>SD</i>)	1.3 (1.8)	20.7 (8.2)*	20.6 (8.2)*
Range	0–8	0–28	0–28
J1. Verbal Fluency			
<i>M</i> (<i>SD</i>)	15.3 (3.5)	7.2 (4.8)*	7.8 (5.1)*
Range	9–26	0–21	0–21
J2. Boston Naming Test [15]			
<i>M</i> (<i>SD</i>)	10.4 (2.5)	6.2 (3.5)*	6.3 (3.6)*
Range	4–15	0–15	0–15
J3. Mini-Mental State [30]			
<i>M</i> (<i>SD</i>)	28.0 (1.7)	16.5 (6.5)*	16.4 (6.9)*
Range	20–30	3–28	3–28
J4. Word List Memory [30]			
<i>M</i> (<i>SD</i>)	17.9 (4.2)	8.0 (4.6)*	8.0 (4.9)*
Range	7–25	0–19	0–19
J5. Constructional Praxis [11]			
<i>M</i> (<i>SD</i>)	10.2 (1.2)	6.8 (2.8)*	6.9 (2.8)*
Range	6–11	0–11	0–11
J6. Word List Recall [10]			
<i>M</i> (<i>SD</i>)	6.4 (1.8)	1.2 (1.5)*	1.1 (1.5)*
Range	1–10	0–6	0–6
J7. Word List Recognition [10]			
<i>M</i> (<i>SD</i>)	9.4 (1.1)	5.7 (11.2)*	4.5 (3.3)*
Range	4–10	0–10	0–10
J8. Constructional Praxis Recall [11]			
<i>M</i> (<i>SD</i>)	6.4 (2.6)	1.6 (1.8)*	1.6 (1.8)*
Range	1–11	0–7	0–7

Table 4. Factor Loading for Three Factors in a Factor Analysis of the Neuropsychological Battery in Dementia Patients ($n = 106$)

Test	Factor 1	Factor 2	Factor 3
Verbal Fluency	0.22	0.84	0.15
Boston Naming Test	0.10	0.80	0.23
Mini-Mental State	0.47	0.68	0.43
Word List Memory	0.68	0.52	0.15
Constructional Praxis	0.05	0.25	0.89
Word List Recall	0.90	0.18	0.07
Word List Recognition	0.85	0.14	0.25
Constructional Recall	0.46	0.18	0.66
Percentage of variance explained	31	28	20



Summary

1. CERAD-K is a considerably reliable and valid equivalent to the English-American version of the CERAD clinical & neuropsychological assessment batteries
2. CERAD-K is certified by CERAD headquarter.
3. We have been establishing a consortium for the efficient registry and systematic multicenter study on dementia.

Development of the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): Clinical and Neuropsychological Assessment Batteries

Jung H. Lee,¹ Kang U. Lee,^{2,3} Dong Y. Lee,^{2,4} Ki W. Kim,^{2,3} Jin H. Jhoo,^{2,4} Ju H. Kim,⁵ Kun H. Lee,⁶
Sung Y. Kim,⁷ Sul H. Han,⁸ and Jong I. Woo^{2,4}

치매 진단평가를 위한 한국판 CERAD 평가집 제1판

CERAD-K

Copyright © 2003

The Korean Version of
Consortium to Establish
Registry for Alzheimer's Disease
Packet, the 1st Edition



Journal of the International Neuropsychological Society (2004), **10**, 72–81.
Copyright © 2004 INS. Published by Cambridge University Press. Printed in the USA.
DOI: 10.1017/S1355617704101094

A normative study of the CERAD neuropsychological assessment battery in the Korean elderly

DONG Y. LEE,¹ KANG U. LEE,² JUNG H. LEE,² KI W. KIM,³ JIN H. JHOO,⁴ SUNG Y. KIM,⁵
JONG C. YOON,⁶ SUNG I. WOO,⁷ JIN HA,⁸ AND JONG I. WOO,^{8,9}

Development of a Korean version of the behavior rating scale for dementia (BRSD-K)

Jong Chul Youn¹, Dong Young Lee^{2*}, Jung Hie Lee³, Ki Woong Kim⁴, Jin Hyeong Jhoo³, Il Han Choo², Yong Su Paek⁵, Yong Ho Jeon⁵, Kwan Woo Seo⁶ and Jong Inn Woo²

¹*Department of Neuropsychiatry, Kyunggi Provincial Hospital for the Elderly, Yongin, Kyunggi-do, Korea*


²*Department of Neuropsychiatry, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Korea*

³*Department of Neuropsychiatry, Kangwon National University College of Medicine and Kangwon National University Hospital, Chuncheon, Kangwon-do, Korea*

⁴*Department of Neuropsychiatry, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Sungnam, Kyunggi-do, Korea*

⁵*Department of Neuropsychiatry, Osan Mental Hospital, Osan, Kyunggi-do, Korea*

⁶*Department of Neuropsychiatry, Andong Mental Hospital, Andong, Kyungsangbuk-do, Korea*



Hospitals using CERAD-K

■ 서울

서울대학교병원 / 서울아산병원 / 건국대학교병원 / 인제대학교백병원
순천향대학교병원 / 대림성모병원

■ 경기

분당서울대학교병원 / 고대안산병원 / 경기도립노인전문병원

■ 강원

강원대학교병원

■ 충청

충남대학교병원 / 단국대학교병원 / 건국대학교충주병원

■ 경상

경북대학교병원 / 동국대학교경주병원 / 경상대학교병원

■ 전라

전주노인복지병원

■ 제주

제주대학교병원

- 2009년 현재 18 Sites -
(2003년 당시 6 Sites)



Future Plans

■ CERAD Center 인증

- 현재 CERAD-K 사용 병원의 표준화 및 등록시스템 수립
- CERAD Headquarter를 중심으로 Network 구성

■ 국내 대단위 연구 수행 본격화

■ 국제공동연구 기획, 참여



Thank You !